Evidence map›Paper›PMID 42201470›Full record

ArticleGeroScience2026

Telomere length dynamics do not predict subclinical atherosclerosis progression over a six-year period.

Vicente Andrés, Juan M Fernández-Alvira, Beatriz Dorado, Ana Guío-Carrión, Ana García-Álvarez, Inés García-Lunar, Antonio Fernández-Ortiz, José J Fuster, Stuart Pocock, Borja Ibáñez and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in GeroScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Vicente Andrés *Centro Nacional de Investigaciones Cardiovasculares (CNIC), Melchor Fernández Almagro 3, Madrid, 28029, Spain. vandres@cnic.es.ORCID http://orcid.org/0000-0002-0125-7209
Juan M Fernández-Alvira *Centro Nacional de Investigaciones Cardiovasculares (CNIC), Melchor Fernández Almagro 3, Madrid, 28029, Spain.ORCID http://orcid.org/0000-0002-4145-5103
Beatriz Dorado *Centro Nacional de Investigaciones Cardiovasculares (CNIC), Melchor Fernández Almagro 3, Madrid, 28029, Spain.ORCID http://orcid.org/0000-0002-1958-4558
Ana Guío-Carrión *Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain.ORCID http://orcid.org/0000-0002-8963-4389
Ana García-ÁlvarezCentro Nacional de Investigaciones Cardiovasculares (CNIC), Melchor Fernández Almagro 3, Madrid, 28029, Spain.ORCID http://orcid.org/0000-0002-1718-2424
Inés García-LunarCentro Nacional de Investigaciones Cardiovasculares (CNIC), Melchor Fernández Almagro 3, Madrid, 28029, Spain.ORCID http://orcid.org/0000-0003-4117-6814
Antonio Fernández-OrtizCentro Nacional de Investigaciones Cardiovasculares (CNIC), Melchor Fernández Almagro 3, Madrid, 28029, Spain.ORCID http://orcid.org/0000-0002-3239-1910
José J FusterCentro Nacional de Investigaciones Cardiovasculares (CNIC), Melchor Fernández Almagro 3, Madrid, 28029, Spain.ORCID http://orcid.org/0000-0002-5970-629X
Stuart PocockCentro Nacional de Investigaciones Cardiovasculares (CNIC), Melchor Fernández Almagro 3, Madrid, 28029, Spain.ORCID http://orcid.org/0000-0003-2212-4007
Borja IbáñezCentro Nacional de Investigaciones Cardiovasculares (CNIC), Melchor Fernández Almagro 3, Madrid, 28029, Spain.ORCID http://orcid.org/0000-0002-5036-254X
María A BlascoCentro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain.ORCID http://orcid.org/0000-0002-4211-233X
Valentín FusterCentro Nacional de Investigaciones Cardiovasculares (CNIC), Melchor Fernández Almagro 3, Madrid, 28029, Spain. vfuster@cnic.es.ORCID http://orcid.org/0009-0005-7344-8425

Funding

Fundación Ramón Areces CIVP21A7006Instituto de Salud Carlos III AC22/00020Instituto de Salud Carlos III PI24/00260Ministerio de Ciencia, Innovación y Universidades CEX2020-001041-SMinisterio de Ciencia, Innovación y Universidades PID2022-141211OB-I00
6 · The paper itself

Abstract

Subclinical atherosclerosis (SA) burden and progression are independently associated with all-cause mortality. However, monitoring SA progression requires reliable and cost-effective biomarkers. While leukocyte telomere length (LTL) attrition has been linked to cardiovascular disease and mortality, it remains uncertain whether changes in LTL over time can predict SA progression. In this study, we conducted a longitudinal study to assess whether accelerated LTL attrition is associated with SA progression over a 6-year period in healthy middle-aged individuals. LTL was measured by high-throughput quantitative fluorescence in-situ hybridization in peripheral-blood leukocyte samples obtained 6 years apart from a sub-cohort of 1068 Progression of Early Subclinical Atherosclerosis (PESA)-study participants. SA was assessed by 3D vascular ultrasound in the carotid and femoral territories. Associations were evaluated using linear and logistic regression models. LTL parameters at baseline and after 6 years showed a positive correlation, but no significant associations were found between changes in LTL and changes in plaque volume over 6 years, either in the total sample or when stratified by sex. Likewise, no significant associations were found between LTL changes and the odds of SA progression over a 6-year period. Similar results were found when considering short telomere load changes. These findings suggest limited utility of LTL dynamics as an early biomarker for SA progression in healthy middle-aged individuals.

Indexed as

PESA cohortProspective studySubclinical atherosclerosis progressionTelomere length dynamics

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.